The Alkermes advantage: Medication adherence can be difficult. Not only does Alkermes develop extended release versions of "important" compounds, their technology makes the drugs WORK BETTER. Period. Exclamation point!
Just parked some of my Amylin gains here a few weeks ago and expect to hang around for a while. The revenue stream from Bydureon and soon to come once monthly as the Seeking Alpha author just wrote can become a cash cow for Alkermes alone. This author gets it and the pipeline is looking strong!
This is going higher imho... Good luck longs - flsh56
Good to see some fellow former AMLN shareholders here. I've always viewed ALKS as an alternative way to play the exenatide franchise. Bydureon and a once-monthly version should have a meaningful impact on ALKS value if things go reasonably well. And ALKS has interesting products and a pipline that should fuel some nice long term growth. Even with the buyout, AMLN has underperformed ALKS over the past 5 years: